An EEG Study of Intravenous Ketamine for Major Depression Disorder

Open-label, single-arm study enrolling 35 adults with MDD to receive four 50–60 minute IV infusions of 60 mg ketamine on days 0, 7, 14 and 21; EEG recorded before, during and after infusions with a follow-up visit at 4 weeks post-treatment.

Objective is to characterise changes in EEG measures associated with ketamine treatment and to monitor safety and tolerability; clinical symptom measures (e.g., MADRS) and adverse events will be collected.